Drug intelligence / Profile preview

KQ-19B CAR-T cells

Development stage: Unknown
Lead developer: Shanghai ChangZheng Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

KQ-19B CAR-T cells are an autologous, dual-targeting chimeric antigen receptor (CAR) T-cell therapy directed against both B-cell maturation antigen (BCMA) and CD19. Developed by Shanghai Changzheng Hospital, this cell therapy is designed to treat relapsed or refractory multiple myeloma by simultaneously targeting two antigens commonly expressed on malignant plasma cells, potentially reducing the risk of relapse due to antigen loss. The therapy is currently undergoing early-phase clinical evaluation to assess its safety, tolerability, and preliminary efficacy in adult patients.

Other names: CD19/BCMA dual-targeting CAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on KQ-19B CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KQ-19B CAR-T cells.

Explore the full profile